We are awaiting results of on-going trials such as RTOG 1306 to help determine whether adding upfront EGFR TKIs to standard concurrent chemo-radiotherapy would benefit patients with unresectable locally advanced EGFR mutated NSCLC [22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.